Incyte Corporation (INCY)
$
65.06
-0.98 (-1.51%)
Key metrics
Financial statements
Free cash flow per share
1.4909
Market cap
12.8 Billion
Price to sales ratio
2.8966
Debt to equity
0.0118
Current ratio
2.0389
Income quality
17.9874
Average inventory
61.4 Million
ROE
0.0064
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Incyte Corporation is a biopharmaceutical company that concentrates on the discovery, development, and commercialization of proprietary therapeutics both in the United States and internationally. The EBITDA is $408,158,000.00 a key indicator of the company's operational profitability. The gross profit stands at $3,929,117,000.00 highlighting the company's profitability from core operations. Among its noteworthy products, Incyte offers JAKAFI, which is utilized for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that serves as an oncogenic driver in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor designed to treat chronic myeloid leukemia as well as Philadelphia-chromosome positive acute lymphoblastic leukemia. Furthermore, the company provides a range of clinical stage products, such as ruxolitinib for steroid-refractory chronic graft-versus-host disease (GVHD), itacitinib in Phase II/III clinical trials for naive chronic GVHD, and pemigatinib for treating bladder cancer, cholangiocarcinoma, and tumor-agnostic conditions. The company's stock is identified with the symbol 'INCY' in the market, and it reported an income before tax of $316,630,000.00 showcasing its pre-tax profitability. Additionally, the operating income ratio is 0.01 indicating the company's operational profitability margin. Incyte also collaborates with various pharmaceutical companies to expand its research and development efforts. With a mid-range market capitalization of $12,593,664,200.00 Incyte is a steady performer in the biopharmaceutical sector. The stock is reasonably priced at $66.04 appealing to a broad range of investors. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, the stock has a high average trading volume of 2,046,687.00 indicating strong liquidity. As part of the Healthcare sector, the company drives innovation and growth, continuously working on new therapies and treatment options. Its collaborations with leading companies in the field and numerous clinical trials underscore its commitment to advancing medical science and improving patient outcomes in challenging diseases.
Is Incyte Corporation (INCY) a good investment?
Investing in Incyte Corporation (INCY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Incyte Corporation (INCY)'s stock forecast?
Analysts predict Incyte Corporation stock to fluctuate between $53.56 (low) and $83.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Incyte Corporation's market capitalization?
As of 2025-05-30, Incyte Corporation's market cap is $12,593,664,200, based on 193,570,000 outstanding shares.
How does Incyte Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Incyte Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Incyte Corporation (INCY) stock?
To buy Incyte Corporation (INCY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for INCY. Place an order (Market, Limit, etc.).
What is the best time to invest in Incyte Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Incyte Corporation stock ever split?
Incyte Corporation's last stock split was 2:1 on 2000-09-01.
How did Incyte Corporation perform in the last earnings report?
Revenue: $4,241,217,000 | EPS: $0.16 | Growth: -94.01%.
Where can I find Incyte Corporation's investor relations reports?
Visit https://www.incyte.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Incyte Corporation?
You can explore historical data from here
What is the all-time high and low for Incyte Corporation stock?
All-time high: $94.50 (2021-02-09) | All-time low: $50.27 (2023-10-31).
What are the key trends affecting Incyte Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
zacks.com
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
businesswire.com
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.
seekingalpha.com
Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research and Development Christiana Stamoulis - Executive Vice President and Chief Financial Officer Matteo Trotta - EVP, Head of U.S. Dermatology Mohamed Issa - EVP, Head of U.S. Oncology Steven Stein - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim David Lebowitz - Citi Andrew Barrons - Leerink Partners Tazeen Ahmad - Bank of America Jessica Fye - JPMorgan Chase Marc Frahm - TD Cowen Vikram Purohit - Morgan Stanley Ash Verma - UBS James Shin - Deutsche Bank Salim Syed - Mizuho Securities Gavin Clark-Gartner - Evercore ISI Jay Olson - Oppenheimer Operator Greetings, and welcome to the Incyte's First Quarter 2025 Earnings Conference and Webcast. At this time, all participants are in a listen-only mode.
zacks.com
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
businesswire.com
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing.
investopedia.com
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
barrons.com
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
schaeffersresearch.com
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
See all news
